ArticleBiomedical reports2026
Hesperadin sensitizes gastric cancer cells to cisplatin via NOX1-dependent oxidative stress.
Article in Biomedical reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The therapeutic efficacy of cisplatin in gastric cancer (GC) is frequently constrained by chemoresistance and systemic toxicity. Targeted small molecules hold promise for providing synergistic effects that enhance treatment outcomes. GC cell viability was assessed via a Cell Counting Kit-8 (CCK-8) assay. Apoptosis, intracellular reactive oxygen species (ROS) levels, and the mitochondrial membrane potential were evaluated via flow cytometry and JC-1 staining. Transcriptomic analysis [RNA-sequencing (RNA-Seq)] was subsequently conducted to identify differentially regulated pathways, followed by validation via reverse transcription-quantitative PCR and western blotting. DNA damage was measured by γ-H2AX immunofluorescence, and clonogenic survival was examined. The NOX1-specific inhibitor ML171 was used to verify its mechanistic involvement. Hesperadin markedly suppressed GC cell proliferation in a dose-dependent manner and induced mitochondrial apoptosis by regulating the Bcl-2/Bax ratio and activating caspase pathways. RNA-Seq analysis revealed significant upregulation of NOX1 and activation of oxidative stress-associated pathways following Hesperadin treatment. Cotreatment with Hesperadin and cisplatin markedly reduced the IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.